Duaklir (aclidinium bromide and formoterol fumarate), a long-term maintenance treatment for chronic obstructive pulmonary disease (COPD), is  available to patients living in the U.S., Circassia Pharmaceuticals announced. According to the company, the product became available on Oct. 21. The U.S. Food and Drug Administration…
Tudorza (aclidinium bromide) reduces flare-ups in patients with moderate to severe chronic obstructive pulmonary disease (COPD) without increasing the risk of cardiovascular complications such as heart attack and stroke, or death, data from a Phase 4 trial show. The findings were discussed by Robert Wise, MD,…
Routine evaluation of respiratory function through spirometry after treatment with bronchodilator medicines can help improve diagnosis accuracy for chronic obstructive pulmonary disease (COPD), preventing approximately 39% of overdiagnosis, a new study suggests. Researchers from the University of Kentucky College of Medicine found that using such an assessment…
Former smokers and people who smoke relatively few cigarettes per day may experience a faster decline in lung function than people who have never smoked, although they still have a slower decline in lung function than current smokers, a new study suggests. The study, “Lung function decline…
Bayer will invest more than $30 million over the next five years to fund collaborative research projects focused on finding new treatments for chronic lung diseases, including chronic obstructive pulmonary disease (COPD). The projects will be developed in a new lab launched in collaboration with the founding members of…
Shirts with smart technology could be used in place of traditional laboratory equipment to measure lung function, and prove to be particularly useful in respiratory conditions such as asthma, cystic fibrosis, or chronic obstructive pulmonary disease (COPD), new research suggests. The data were discussed in a presentation, titled…
Michael J. Holtzman, MD, has received close to $7.5 million in total funding for research aimed at developing stem cell-based treatments for chronic obstructive pulmonary disease (COPD), asthma, and other disorders. Holtzman’s research at Washington University School of Medicine in St. Louis identified a subset of stem…
The Dorney-Koppel Family Charitable Foundation put chronic obstructive pulmonary disease in the spotlight, leading the educational grand challenge at the recent Stanford Medicine X | CHANGE 2019 conference. This year’s educational challenge, which lasts until December, will explore and discuss solutions to five critical problems related to chronic…
The RheOx system for the treatment of chronic bronchitis has received the CE mark, an indication that it has met high health, safety, and environmental protection requirements, in the European Union. Developed by Gala Therapeutics, the RheOx system is a minimally invasive tool used to perform a procedure called…
Priority Health will cover Pulmonx’s Zephyr Endobronchial Valve device as a non-surgical treatment option for severe emphysema, a severe form of chronic obstructive pulmonary disease (COPD). The insurer’s new coverage policy is specific to the device marketed by Pulmonx. With this Priority Health decision, some 30 million U.S. residents with…
Get regular updates to your inbox.